PC
BIO icon

Pelham Capital’s Bio-Rad Laboratories Class A BIO Stock Holding History

Pelham Capital’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-184,182
Closed -$64.6M – 10
2020
Q1 		$64.6M Buy
+184,182
New +$67.7M 9.34% 6

Other funds holding BIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
ACM
Atlanta Capital Management Atlanta, Georgia $22.5B AUM 9.67% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Pelham Capital's BIO Position: Q2 2020 in Review

Pelham Capital sold out of Bio-Rad Laboratories Class A (BIO) in Q2 2020, closing a stake of 184,182 shares — an estimated $64.6M sold.

Pelham Capital first reported a position in BIO in Q1 2020 and held it in 1 quarter. The position peaked at $64.6M in Q1 2020. 470 funds tracked by Wall St. Rank hold BIO as of Q2 2020.

  • Pelham Capital reported no remaining Bio-Rad Laboratories Class A position as of Q2 2020 after selling out during the quarter.
  • Pelham Capital sold 184,182 Bio-Rad Laboratories Class A shares in Q2 2020, an estimated $64.6M.
  • Pelham Capital first reported a position in Bio-Rad Laboratories Class A in Q1 2020 and held it in 1 quarter.
  • Pelham Capital's Bio-Rad Laboratories Class A position peaked at $64.6M in Q1 2020.
  • 470 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2020.

Based on Pelham Capital's 13F filing for Q2 2020, filed 24 Jul 2020.